Mesoblast Limited
MESO
$16.14
-$0.25-1.53%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
9/9/2026
-
Tickeron - Stocks
Mesoblast (MESO, $16.39) entered Downtrend as Momentum indicator drops below 0 level on Sep 08, 2026
9/9/2026
-
Tickeron - Stocks
9/5/2026
-
The Cerbat Gem
Mesoblast (MESO, $17.14) entered Downtrend as Momentum indicator drops below 0 level on Sep 03, 2026
9/4/2026
-
Tickeron - Stocks
9/4/2026
-
MarketBeat
9/4/2026
-
MarketBeat
9/2/2026
-
Tickeron - Stocks
9/2/2026
-
Tickeron - Stocks
8/30/2026
-
TipRanks
8/30/2026
-
TipRanks
8/29/2026
-
Tickeron - Stocks
8/28/2026
-
TipRanks
8/27/2026
-
MarketBeat
8/27/2026
-
TipRanks: TheFly
8/27/2026
-
SeekingAlpha
8/27/2026
-
Seeking Alpha: Transcripts
8/27/2026
-
TipRanks
8/27/2026
-
Globe Newswire
8/27/2026
-
MarketBeat
8/26/2026
-
Benzinga
8/26/2026
-
TipRanks
8/26/2026
-
TipRanks
8/24/2026
-
Globe Newswire
8/24/2026
-
TipRanks
8/24/2026
-
TipRanks
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, August 26, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Feb 22 and 26 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
61 3 9639 6036
Address
55 Collins Street
Level 38
Melbourne, VIC 3000
Level 38
Melbourne, VIC 3000
Country
Year Founded
Business Description
Sector
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company’s proprietary regenerative medicine technology platform...
more